Scaling cell-based vaccine manufacturing: process redesign achieves an approximately 20-fold increase in relative viral titer

Scaling adherent viral vaccine processes in roller bottles often increases operational burden in proportion to production capacity, with vessel count, manual handling, and staffing becoming limiting before cell biology does. This article describes a process redesign that combined a new cell line with a consolidated static culture platform, resulting in an approximately 20-fold increase in relative viral titer, a 60% reduction in operators (from five to two), an 86% reduction in units handled (from 400–57), a reduction in processing time from 4.5–1.5 h, and an antibiotic-free process, with animal and serological studies confirming that the final product maintained its expected characteristics and immunological response.

When operations, not biology, limit adherent vaccine processes

Animal vaccine manufacturing has relied on adherent culture systems for decades, and roller bottles remain one of the most established platforms across the industry. However, as production demand increases, scaling an adherent process often means scaling the operation itself, because more culture vessels require more operations, more handling steps, and more space. As a result, operational burden grows in line with production capacity, and in many cases the operational side becomes the limiting factor before cell biology does.

Please enter your email to access content Read now